


A sensitive determination of bisphenol A and its 11 analogs and triclosan in urine by UPLC-MS/MS

Éric Gaudreau, Sébastien Gagné, Patrick Bélanger and Normand Fleury

Centre de Toxicologie du Québec (CTQ), Institut national de santé publique du Québec (INSPQ), Québec, Canada ; www.inspq.qc.ca/ctq ; eric.gaudreau@inspq.qc.ca

Introduction


Bisphenol A (BPA) is used mainly as a monomer in the plasticizers with polycarbonate base or in epoxy resins. BPA is found in many consumer products (canned food, thermal paper, etc.). BPA is considered as an endocrine disruptor and because of regulatory actions and public health concerns, it was replaced by similar structure analog compounds by the industry. The effect of these alternate compounds on human health is still largely unknown. Triclosan is used as an antibacterial and antifungal agent in different consumer products (anti-bacterial soaps, toothpaste and deodorants). It is also considered as a suspected endocrine disruptor.



Objectives

- To measure a large panel of BPA analogs and triclosan in a single run with good sensitivity, precision and accuracy.
- To present factors to consider to control the contamination and the hydrolysis step.
- To observe the rate of detection for BPA analogs in urine of the general population.

Methodology



Chromatograms

Figure 1. Chromatograms of BPA and its analogs and triclosan and their respective internal standards in spiked diluted urine.




Table 1. Performance parameters for BPA, its analogs and triclosan analysis by UPLC-MS/MS.

Analyte	Limit of detection (LOD)* (µg/L)	Limit of quantification (LOQ) (µg/L)	Linearity (µg/L)	Matrix effect (%)	Intra-day precision		Inter-day precision (%)
					(%)	Concentration (µg/L)	
BPA	0.021	0.071	LOQ to 25	100 ± 1	1.4	1.3	4.6
BPB	0.0068	0.023	LOQ to 1.0	97 ± 3	6.2	0.036	6.1
BPC	0.082	0.27	LOQ to 2.5	91 ± 8	8.1	0.085	14
BPE	0.0079	0.027	LOQ to 1.0	95 ± 2	3.2	0.061	4.6
BPF	0.028	0.094	LOQ to 50	100 ± 3	3.3	0.65	5.4
BPS	0.016	0.054	LOQ to 25	89 ± 10	3.6	0.78	4.3
BPZ	0.026	0.085	LOQ to 5.0	91 ± 2	5.7	0.18	5.2
BPAF	0.067	0.22	LOQ to 10	97 ± 3	5.5	0.37	8.6
BPAP	0.017	0.056	LOQ to 1.0	82 ± 16	5.0	0.035	5.1
BPA TM	0.069	0.23	LOQ to 7.5	93 ± 6	8.1	0.26	12
BP 4,4'	0.046	0.15	LOQ to 5.0	108 ± 4	1.8	0.36	4.8
DHDPE	0.050	0.17	LOQ to 25	108 ± 3	3.6	1.6	8.0
Triclosan	1.0	3.3	LOQ to 1250	102 ± 5	1.9	3.5	9.3

*Methodological limit of detection (LOD) = 3 times the SD of 30 determinations of human urine measured in 30 different days. Not possible to evaluate recovery because of the derivatization step at the beginning of the process.

- Adequate LODs in human urines according to expected reference levels.
- Good levels of precision and linearity obtained.
- Matrix effects well corrected by the internal standards.

Method accuracy

Table 2. Method accuracy for BPA, BPF, BPS, BPZ and triclosan based on participation in External Quality Assessment Schemes.

Analyte	Program 2023	Measured value (µg/L)	Reference value (µg/L)	z'-score	Tolerance range (µg/L)
BPA	G-EQUAS (RV 71A)	1.24	1.21	-	0.82 - 1.60
	G-EQUAS (RV 71B)	14.61	14.62	-	11.47 - 17.77
	G-EQUAS (RV 72A)	0.95	0.81	-	0.54 - 1.08
BPF	G-EQUAS (RV 72B)	3.48	3.21	-	2.31 - 4.11
	G-EQUAS (RV 71A)	1.66	1.68	-	1.32 - 2.04
	G-EQUAS (RV 71B)	4.49	4.59	-	3.78 - 5.40
BPS	G-EQUAS (RV 72A)	0.60	0.66	-	0.48 - 0.84
	G-EQUAS (RV 72B)	2.24	2.42	-	1.97 - 2.87
	G-EQUAS (RV 71A)	0.62	0.63	-	0.45 - 0.81
Triclosan	G-EQUAS (RV 71B)	3.12	3.30	-	2.67 - 3.93
	G-EQUAS (RV 72A)	0.38	0.35	-	0.26 - 0.44
	G-EQUAS (RV 72B)	0.91	0.92	-	0.71 - 1.13
BPA ¹	G-EQUAS (RV 71A)	11.2	11.0	-	7.1 - 14.9
	G-EQUAS (RV 71B)	53.5	54.7	-	39.4 - 70.0
	G-EQUAS (RV 72A)	2.3	2.5	-	1.6 - 3.4
BPF ¹	G-EQUAS (RV 72B)	25.1	25.5	-	18.9 - 32.1
	OSEQAS OS-U-E2303	1.77	1.74	0.08	1.01 - 2.47
	OSEQAS OS-U-E2304	1.23	1.31	-0.29	0.722 - 1.90
BPS ¹	OSEQAS OS-U-E2305	0.523	0.645	-0.58	0.221 - 1.07
	OSEQAS OS-U-E2306	1.58	1.70	-0.33	0.985 - 2.42
	OSEQAS OS-U-E2303	4.39	3.31	1.32	1.67 - 4.95
BPZ ¹	OSEQAS OS-U-E2304	0.662	0.641	0.16	0.378 - 0.904
	OSEQAS OS-U-E2305	0.170	0.174	-0.06	0.0486 - 0.299
	OSEQAS OS-U-E2306	0.858	0.803	0.32	0.459 - 1.15
Triclosan ¹	OSEQAS OS-U-E2303	0.642	0.519	1.08	0.292 - 0.746
	OSEQAS OS-U-E2304	1.56	1.53	0.08	0.913 - 2.15
	OSEQAS OS-U-E2305	0.327	0.320	0.11	0.190 - 0.450
BPAF ¹	OSEQAS OS-U-E2306	0.988	0.964	0.12	0.578 - 1.35
	OSEQAS OS-U-E2303	0.939	0.829	0.61	0.470 - 1.19
	OSEQAS OS-U-E2304	1.01	0.845	0.94	0.497 - 1.19
BPAP ¹	OSEQAS OS-U-E2305	< LOD	-	-	-
	OSEQAS OS-U-E2306	0.541	0.498	0.43	0.296 - 0.700
	OSEQAS OS-U-E2303	211	195	0.40	116 - 274
Triclosan ¹	OSEQAS OS-U-E2304	666	647	0.12	341 - 953
	OSEQAS OS-U-E2305	< LOD	-	-	-
	OSEQAS OS-U-E2306	390	395	-0.06	217 - 573


¹ Data not shown for OSEQAS OS-U-E2301 and OSEQAS OS-U-E2302.

- Excellent comparability with other laboratories participating to German External Quality Assessment Scheme (G-EQUAS; Erlangen, Germany) and External Quality Assessment Scheme for Organic Substances (OSEQAS/CTQ; Québec, Canada)
- Most of the results for G-EQUAS are below 10% of deviation from the reference values.
- Most of the z'-scores are below 1.0 for BPA, BPF, BPS, BPZ and triclosan. Z'-score ≤ 1.0 is considered perfect and ≤ 2.0 satisfactory by the program OSEQAS.

Contamination precautions

- All glass tubes must be heated at 500°C.
- All glassware and pipette tips must be washed with dichloromethane to reduce external contamination from dust.
- All reagents used (acetate buffer, carbonate buffer, β-glucuronidase and pyridine 3-sulfonyl chloride) must be monitored to control contamination.
- Pyridine 3-sulfonyl chloride may be a possible source of BPF while acetate buffer and β-glucuronidase could be possible sources of BPA, BP 4,4' and BPS.

Monitoring deconjugation step



- Two labeled glucuronide standards (BPA-d₆ glucuronide and BPS-d₈ glucuronide) were added to each sample to measure the enzymatic hydrolysis efficiency.
- The added concentration for these glucuronide standards corresponded to the concentration of a calibration curve point (C-7) for BPA and BPS.
- An hydrolysis yield > 80% for both analytes must be obtained to validate the efficiency of the enzyme and to validate the analysis.

Method application

Table 3. Proportion of analytes detected and geometric mean from a reference population recruited in our organization in 2018.

Analyte	LOD (µg/L)	N	% > LOD	Min (µg/L)	Max (µg/L)	Median (µg/L)	Geometric mean (µg/L)	Geometric mean CHMS ¹ (µg/L)
BPA	0.021	65	100	0.099	4.3	0.88	0.78	0.68
BPE	0.0079	65	95.4	0.008	0.30	0.033	0.032	0.023
BPF	0.028	65	100	0.072	94	0.35	0.60	0.12
BPS	0.016	65	100	0.050	3.0	0.37	0.37	0.37
BPZ	0.026	65	0.2	<LOD	0.036	-	-	-
BP 4,4'	0.046	65	98.5	0.069	3.5	0.47	0.43	0.35
DHDPE	0.050	65	100	0.056	11	1.1	1.1	- ²
Triclosan	1.0	50	64	<LOD	1325	2.0	86	-
BPB	0.068	65	0	<LOD	<LOD	-	-	-
BPC	0.082	65	0	<LOD	<LOD	-	-	-
BPAF	0.067	65	0	<LOD	<LOD	-	-	-
BPAP	0.017	65	0	<LOD	<LOD	-	-	-
BPA TM	0.069	65	0	<LOD	<LOD	-	-	-

¹ Levels of environmental chemicals in the Canadian population from the Canadian Health Measures Survey (CHMS), Cycle 6, 2018-2019, The Canadian Biomonitoring Dashboard, <https://infobase-dev.com/chms/>.
² Not quantified in CHMS.

- BPA, BPE, BPF, BPS, BP 4,4', DHDPE and triclosan are the most frequently detected analytes in the general population.
- Geometric means obtained from our sampled population are comparable with the geometric means obtained from the Canadian Health Measures Survey (CHMS) Cycle 6 2018-2019, except for BPF.
- Triclosan is most frequently detected in our sampled population (64%) compared to CHMS Cycle 6 2018-2019 (47.5%).

Conclusion

- The current method has a good sensitivity, precision and accuracy to measure a large panel of BPA analogs and triclosan in a single run.
- Heating the glass tubes and washing the glassware and pipette tips are a good way to control contamination.
- Adding glucuronide conjugated standards is useful to evaluate the efficiency of the enzymatic hydrolysis step.
- BPA, BPE, BPF, BPS, BP 4,4' and DHDPE are detected between 95-100% of samples in the general population.
- This method is suitable for human biomonitoring studies.

This method is currently used for the Canadian Health Measures Survey (CHMS) Cycle 7: 2023-2025 (4800 samples).